/
RCKT
$3.37+$0.12 (+3.69%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$354.9M
109M shares
52-week range
$2.40 – $5.45
32% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.29%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-42.86
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $330.0K | $426.0K | $1.1M | $0 | $0 | $0 | $0 | $11.0M |
| Gross profit | −$330.0K | −$426.0K | −$1.1M | $0 | $0 | $0 | $0 | −$11.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $53.3M | $58.6M | $106.4M | $125.5M | $165.6M | $186.3M | $171.2M | $142.0M |
| Operating income | −$71.2M | −$76.2M | −$136.0M | −$167.2M | −$224.3M | −$259.7M | −$273.2M | −$228.5M |
| EBITDA | −$71.2M | −$71.1M | −$131.6M | −$157.8M | −$213.7M | −$236.6M | −$247.5M | −$210.2M |
| Net income | −$74.5M | −$83.2M | −$146.7M | −$169.1M | −$221.9M | −$245.6M | −$258.7M | −$223.1M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.89 | -1.70 | -2.52 | -2.68 | -3.26 | -2.92 | -2.73 | -2.01 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.20 | $-0.34–$-0.03 | 9 |
| 2027 | $20M | $-1.29 | $-1.61–$-0.85 | 7 |
| 2028 | $65M | $-0.92 | $-1.86–$0.69 | 7 |
| 2029 | $170M | $-0.45 | $-0.71–$-0.06 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.47
Price
$3.37
Implied downside
-86%
Peer comparison
Rocket Pharmaceuticals, Inc. Common Stock
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
www.rocketpharma.com- Employees
- 202
- IPO / List date
- Feb 18, 2015
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds RCKT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 637,174 | $2.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded RCKT yet.
